^
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
MYC overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
EZH2 overexpression
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Resistant: C3 – Early Trials
MYC rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials
BCL6 rearrangement
Mediastinal B Cell Lymphoma
rituximab
Sensitive: C3 – Early Trials